Skip to content

Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec

Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02153346
Enrollment
101
Registered
2014-06-03
Start date
2014-06-22
Completion date
2016-04-22
Last updated
2018-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

indirect cost, asthma

Brief summary

Rationale Asthma is a chronic inflammatory disorder of the airways affecting persons of all ages and is recognized as one of the most common chronic diseases. Canada has one of the highest asthma prevalence rates in the world (8.5%, aged 12 and over) and it is a major cause of hospitalization. The cost of asthma varies dramatically across disease severity, and it is expected that these costs are greater when the condition is sub-optimally managed and controlled. Although a number of publications have been reported on the economic burden of asthma, there is a lack of information on the cost of asthma based on disease severity and level of disease control in Canada. The proposed study aims to i) estimate the annual indirect cost of asthma and ii) the impact of asthma on absenteeism, presenteeism and work productivity in Canada. This information is essential to further quantify the burden of asthma on patients and the healthcare system in the Canadian setting. Overall Objectives The overall objective of this study is to describe the impact of asthma on patients with moderate to severe asthma and to estimate the indirect costs of asthma care in asthmatic patients followed in tertiary clinics specialized in the field of asthma in Quebec, Canada. Study Design A prospective cohort study will be conducted to measure the indirect economical burden of asthma on patients. Patients will be selected and recruited from the BD-Asthma registry and followed prospectively for 1 year. Recruited patients will be asked to complete questionnaires at regular intervals for 1 year to measure indirect cost of disease, using the Valuation of lost productivity (VOLP) questionnaire. Data Collected For each patient, the following data will be collected * Patient demographics * Age * Sex * Income * Level of education * Smoking * Disease management and Treatment utilization in the year prior to recruitment * Physician visits and follow up * Hospitalizations (number and total days) * Emergency room visits * Disease characteristics * Asthma history * Year of first diagnosis of asthma severity * Asthma Control Questionnaire score * Lung function measures Data Analysis Methods For each participant, the percentage of time missed from work over a year will be calculated. We will use the human capital approach to calculate the costs of asthma due to lost productivity, incorporating both absenteeism and presenteeism in the calculation of the productivity loss. We will calculate the number of work days in which the person was unable to attend the workplace, and the number of days and percentage of time lost during the days the person's work was affected by their asthma. The fraction of time lost from work in the past year will be multiplied by the average income in Quebec. Finally, this value will be multiplied by the coefficient generated by the VOLP, which reflects the relative value of the productivity loss. In addition, we will calculate the VOLP multiplier for each participant which, combined with the percentage of time missed from work, will create a measure of productivity loss adjusted for the relative importance and replace-ability of the participant's profession. Sample Size and Power One hundred subjects will be randomly selected from the BD-Asthma registry. Limitations The study population may not be representative of the general asthma population, as moderate to severe asthma will be over represented in these tertiary centers.

Detailed description

Rationale Asthma is a chronic inflammatory disorder of the airways affecting persons of all ages and is recognized as one of the most common chronic diseases. With a continuously increasing prevalence and associated morbidity and mortality, asthma poses a tremendous clinical and economic burden on healthcare systems and on the society as a whole. According to a report published by the Global Initiative for Asthma (GINA) in 2004 an estimated 300 million people in the world have asthma, and more than 2 million Canadians have asthma. Canada has one of the highest asthma prevalence rates in the world (8.5%, aged 12 and over) and it is a major cause of hospitalization. The direct and indirect costs associated with asthma are expected to rank among the highest for chronic diseases due to the high prevalence in conjunction with the significant healthcare utilization associated with the disease and the considerable restrictions asthma imposes on the physical, emotional, social, and professional lives of sufferers. The cost of asthma varies dramatically across disease severity, and it is expected that these costs are greater when the condition is sub-optimally managed and controlled. Although a number of publications have been reported on the economic burden of asthma, there is a lack of information on the cost of asthma based on disease severity and level of disease control in Canada. Moreover, no study has compared the annual cost of uncontrolled and well-controlled asthma patients. Although population-level direct costs have been previously reported through the use of administrative healthcare databases in various provinces, these databases cannot provide clinical data and are limited to subjects who have a public drug insurance plan. The proposed study aims to i) estimate the annual indirect cost of asthma and ii) the impact of asthma on absenteeism, presenteeism and work productivity in Canada. This information is essential to further quantify the burden of asthma on patients and the healthcare system in the Canadian setting. Overall Objectives The overall objective of this study is to describe the impact of asthma on patients with moderate to severe asthma and to estimate the indirect costs of asthma care in asthmatic patients followed in tertiary clinics specialized in the field of asthma in Quebec, Canada. Primary objectives * To estimate the annual indirect costs of asthma in asthmatic patients followed in tertiary clinics specialized in the field of asthma in Quebec, Canada * To estimate the annual indirect cost of asthma by asthma severity and control status (uncontrolled, partly controlled, well controlled) of asthmatic patients followed in tertiary clinics specialized in the field of asthma in Quebec, Canada Secondary objectives • To determine the impact of asthma on work productivity in asthmatic patients followed in tertiary clinics specialized in the field of asthma in Quebec, Canada. Study Design A prospective cohort study will be conducted to measure the indirect economical burden of asthma on patients. Patients will be selected and recruited from the BD-Asthma registry and followed prospectively for 1 year. Recruited patients will be asked to complete questionnaires at regular intervals for 1 year to measure indirect cost of disease, using the Valuation of lost productivity (VOLP) questionnaire. Recruitment of patients All eligible patients from the BD-asthma will be invited to participate. Patients approached for participation will be provided verbal and written information on the project and, if the patient agrees to participate, they will be asked to sign the participation consent form. The forms will be collected by the research coordination centre (either at the clinic or the physicians' office or directly with the patient). All recruited eligible patients that have provided their consent will be included in this study. Source Population The population is defined as individuals diagnosed with asthma (ICD9 codes 493.x). Study Population The study population is defined as having had at least one diagnosis of asthma (ICD9 codes 493.x) recorded in the BD Asthma database between February 2010 and February 2012. Clinical information Patient characteristics and clinical information on asthma will be obtained from the BD-asthma database. Data Collected For each patient, the following data will be collected * Patient demographics * Age * Sex * Income * Level of education * Smoking * Disease management and Treatment utilization in the year prior to recruitment * Physician visits and follow up * Hospitalizations (number and total days) * Emergency room visits * Disease characteristics * Asthma history * Year of first diagnosis of asthma severity * Asthma Control Questionnaire score * Lung function measures Data Analysis Methods For each participant, the percentage of time missed from work over a year will be calculated. We will use the human capital approach to calculate the costs of asthma due to lost productivity, incorporating both absenteeism and presenteeism in the calculation of the productivity loss. We will calculate the number of work days in which the person was unable to attend the workplace, and the number of days and percentage of time lost during the days the person's work was affected by their asthma. The fraction of time lost from work in the past year will be multiplied by the average income in Quebec. Finally, this value will be multiplied by the coefficient generated by the VOLP, which reflects the relative value of the productivity loss. In addition, we will calculate the VOLP multiplier for each participant which, combined with the percentage of time missed from work, will create a measure of productivity loss adjusted for the relative importance and replace-ability of the participant's profession. Sample Size and Power One hundred subjects will be randomly selected from the BD-Asthma registry. Limitations The study population may not be representative of the general asthma population, as moderate to severe asthma will be over represented in these tertiary centers.

Interventions

OTHERValuation of lost productivity questionnaire

A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.

OTHERWork productivity and activity impairment questionnaire

A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.

Sponsors

GlaxoSmithKline
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Part of the BD-Asthma registry * Age 18 years and older * Patients who signed consent for research with the BD-Asthma registry and signed consent to participate in the indirect cost study. * Must be alive at the time of recruitment

Exclusion criteria

• Patients with a diagnosis of COPD recorded in BD-Asthma at the time of enrolment.

Design outcomes

Primary

MeasureTime frameDescription
Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL and at 12-month FUPParticipants completed questionnaires within 2 weeks post-recruitment, 4, 8 and 12 months to measure indirect cost of disease, specifically related to productivity. The following questionnaires were used: WPAI helps to determine presenteeism, absenteeism, and total cost calculation (TCC) possible (number of days during the year of study), while VOLP is used to assess the impact of health conditions on lost productivity in monetary units (United states dollars). The following parameters were calculated: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).
Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL and 12-month FUPCosts of asthma are greater when the asthma is sub-optimally managed and controlled and varies depending on the par. asthma control. Asthma control was assessed using the Asthma Control Questionnaire (ACQ) and par. were asked to recall their experiences during the previous week and respond to the 6 specified questions on a 7-point Likert scale (0=well-controlled; 6=maximum impairment \[poorly controlled\]; a score of ≤0.75 indicates well controlled symptoms. The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA). Only 59 par. were active workers. When stratified by asthma control and severity each stratum had a sample less than 59. Although results are presented. data may not be reliable due to the low number of par. in each stratum.
Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL and 12-month FUPCosts of asthma may vary depending on the participant's asthma severity. Asthma severity was based on the standard definitions for severity and ACQ scores: Mild (\<0.75), Moderate (\>0.75) and Severe (any ACQ score). The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).

Secondary

MeasureTime frameDescription
Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time PointsAt BL, 4-Month, 8-Month and 12-Month FUPWPAI is a self-administered instrument to determine the degree to which asthma affected work productivity while at work and affected activities outside of work in the last 7 days and yields 4 types of scores: Absenteeism (work time missed/missed due to other reasons); Presenteeism (actual time worked); Work Productivity Loss (affected productivity while working); and Activity Impairment (affected regular activities). The following parameters were presented: Hours (Hrs) missed due to asthma (HMA), Hrs missed due to other reasons (HMO), and Hrs actually worked (HAW); all in the last 7 days.

Countries

Canada

Participant flow

Recruitment details

Participants (par.) in this cohort study were randomly selected from the BD-Asthma/RESP registry in Quebec, with an asthma diagnosis between June 2014 and January 2015, more than 18 years of age, and followed at the outpatient clinics of Hôpital du Sacré-Coeur de Montréal (HSCM), a tertiary care clinic specialized in asthma.

Pre-assignment details

187 participants were selected in the BD-Asthma/RESP database; 160 were contacted of which 101 participants were enrolled in the study. 59 refused to participate. Participants were not assigned to any investigational therapies.

Participants by arm

ArmCount
BD-Asthma/RESP
Data was collected by an interview, questionnaires and by review of the medical chart from participants who accepted to be registered in the BD-Asthma/RESP data base.
101
Total101

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up11

Baseline characteristics

CharacteristicBD-Asthma/RESP
Age, Continuous53.5 Years
STANDARD_DEVIATION 14
Age of Asthma onset32.7 Years
STANDARD_DEVIATION 19.1
Asthma severity
Mild
1 Participants
Asthma severity
missing
18 Participants
Asthma severity
Moderate
56 Participants
Asthma severity
Severe
26 Participants
BMI
<18.5
3 Participants
BMI
18.5-24.9
18 Participants
BMI
25.0-29.9
38 Participants
BMI
>=30.0
39 Participants
BMI
missing
3 Participants
Control1.4 ACQ Score
STANDARD_DEVIATION 0.9
Education
College
15 Participants
Education
High school
27 Participants
Education
missing
1 Participants
Education
None
9 Participants
Education
University
41 Participants
Employment Status
Full time
37 Participants
Employment Status
Part-time as an employee
13 Participants
Employment Status
Retired
35 Participants
Employment Status
Self-employed
9 Participants
Employment Status
Unemployed but seeking work
1 Participants
Employment Status
Work disability
6 Participants
FEV189.3 Percent predicted
STANDARD_DEVIATION 23
FEV1/FVC75.1 Percent
STANDARD_DEVIATION 9.4
Number of years at the HSCM asthma clinic10.4 years
STANDARD_DEVIATION 9
Number of years with asthma20.7 Years
STANDARD_DEVIATION 16.7
Sex: Female, Male
Female
65 Participants
Sex: Female, Male
Male
36 Participants
Smoking habits
Current smokers
10 Participants
Smoking habits
Ex-smokers
44 Participants
Smoking habits
missing
1 Participants
Smoking habits
Never smokers
46 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Indirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUP

Costs of asthma are greater when the asthma is sub-optimally managed and controlled and varies depending on the par. asthma control. Asthma control was assessed using the Asthma Control Questionnaire (ACQ) and par. were asked to recall their experiences during the previous week and respond to the 6 specified questions on a 7-point Likert scale (0=well-controlled; 6=maximum impairment \[poorly controlled\]; a score of ≤0.75 indicates well controlled symptoms. The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA). Only 59 par. were active workers. When stratified by asthma control and severity each stratum had a sample less than 59. Although results are presented. data may not be reliable due to the low number of par. in each stratum.

Time frame: BL and 12-month FUP

Population: Source Population. Only participants with available data in each category (represented by n=X in the category title) were analyzed. One third of the participants selected were retired. Only 59 participants were active workers. Therefore the stratification for asthma control and severity included very low numbers (52 at BL; 40 at FUP).

ArmMeasureGroupValue (MEAN)Dispersion
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Partly controlled, CAA, n=9557.65 Canadian DollarsStandard Deviation 1380.41
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Partly controlled, CAA, n=10171.66 Canadian DollarsStandard Deviation 266.7
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Partly controlled, CPA, n=1057.04 Canadian DollarsStandard Deviation 168.54
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Partly controlled, CPA, n=1032.51 Canadian DollarsStandard Deviation 50.72
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Partly controlled, CAA TCC, n=8585.29 Canadian DollarsStandard Deviation 1473.06
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Partly controlled, CAA TCC possible, n=10171.66 Canadian DollarsStandard Deviation 266.7
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL,Partly controlled, CPA TCC, n=871.30 Canadian DollarsStandard Deviation 188.04
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Partly controlled, CPA TCC, n=1032.51 Canadian DollarsStandard Deviation 50.72
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Partly controlled, TICA, n=8656.59 Canadian DollarsStandard Deviation 1660.3
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Partly controlled, TICA, n=10204.18 Canadian DollarsStandard Deviation 296.69
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Uncontrolled, CAA, n=2196.09 Canadian DollarsStandard Deviation 233.01
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Uncontrolled, CAA, n=1539.75 Canadian DollarsStandard Deviation 73.72
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Uncontrolled, CPA, n=229.20 Canadian DollarsStandard Deviation 34.71
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Uncontrolled, CPA, n=149.34 Canadian DollarsStandard Deviation 25.8
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Uncontrolled, CAA TCC, n=20100.89 Canadian DollarsStandard Deviation 238
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Uncontrolled, CAA TCC, n=1345.86 Canadian DollarsStandard Deviation 77.69
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Uncontrolled, CPA TCC, n=2010.12 Canadian DollarsStandard Deviation 36.36
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Uncontrolled, CPA TCC, n=1010.06 Canadian DollarsStandard Deviation 26.71
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Uncontrolled, TICA, n=20111.01 Canadian DollarsStandard Deviation 239.72
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Uncontrolled, TICA, n=1355.92 Canadian DollarsStandard Deviation 99.75
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Well controlled, CAA, n=22278.92 Canadian DollarsStandard Deviation 949.43
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Well controlled, CAA, n=1533.53 Canadian DollarsStandard Deviation 90.66
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL,Well controlled, CPA, n=184.02 Canadian DollarsStandard Deviation 12.84
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Well controlled, CPA, n=1511.8 Canadian DollarsStandard Deviation 32.68
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL,Well controlled, CAA TCC, n=1896.23 Canadian DollarsStandard Deviation 251.82
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Well controlled, CAA TCC, n=1435.92 Canadian DollarsStandard Deviation 93.59
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL, Well controlled, CPA TCC, n=184.02 Canadian DollarsStandard Deviation 12.84
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Well controlled, CPA TCC, n=1412.65 Canadian DollarsStandard Deviation 33.74
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPBL,Well controlled, TICA, n=18100.25 Canadian DollarsStandard Deviation 263.14
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Control Per Participant Per 3 Months at BL and 12-month FUPFUP, Well controlled, TICA, n=1448.57 Canadian DollarsStandard Deviation 94.44
Primary

Indirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUP

Costs of asthma may vary depending on the participant's asthma severity. Asthma severity was based on the standard definitions for severity and ACQ scores: Mild (\<0.75), Moderate (\>0.75) and Severe (any ACQ score). The following parameters were presented: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).

Time frame: BL and 12-month FUP

Population: Source Population. Only participants with available data in each category (represented by n=X in the category title) were analyzed. One third of the participants selected were retired. Only 59 participants were active workers. Therefore the stratification for asthma control and severity included very low numbers (52 at BL; 40 at FUP).

ArmMeasureGroupValue (MEAN)Dispersion
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Mild, CAA, n=1154.36 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Mild, CAA, n=1303.74 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Mild, CPA, n=10.00 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Mild, CPA n=10.00 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Mild, CAA TCC, n=1154.36 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Mild, CAA TCC, n=1303.74 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Mild, TICA, n=1154.36 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Mild, TICA, n=1303.74 Canadian DollarsStandard Deviation 0
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Moderate, CAA, n=30210.09 Canadian DollarsStandard Deviation 803.66
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Moderate, CAA, n=2167.75 Canadian DollarsStandard Deviation 160.89
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Moderate, CPA, n=318.32 Canadian DollarsStandard Deviation 29.8
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Moderate, CPA, n=198.62 Canadian DollarsStandard Deviation 22.19
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Moderate, CAA TCC, n=2867.81 Canadian DollarsStandard Deviation 139.95
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Moderate, CAA TCC, n=1879.05 Canadian DollarsStandard Deviation 171.85
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Moderate, CPA TCC, n=289.21 Canadian DollarsStandard Deviation 31.28
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Moderate, CPA TCC, n=189.10 Canadian DollarsStandard Deviation 22.72
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Moderate, TICA, n=2877.0 Canadian DollarsStandard Deviation 143.12
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Moderate, TICA, n=1888.14 Canadian DollarsStandard Deviation 176.35
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Severe, CAA, n=10553.96 Canadian DollarsStandard Deviation 1319.4
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Severe, CAA, n=7103.16 Canadian DollarsStandard Deviation 229.93
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Severe, CPA, n=959.52 Canadian DollarsStandard Deviation 178.57
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Severe, CPA, n=827.99 Canadian DollarsStandard Deviation 54.9
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Severe, CAA TCC, n=8650.38 Canadian DollarsStandard Deviation 1475.45
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Severe, CAA TCC, n=7103.16 Canadian DollarsStandard Deviation 229.93
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Severe, CPA TCC, n=866.96 Canadian DollarsStandard Deviation 189.4
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Severe, CPA TCC, n=731.99 Canadian DollarsStandard Deviation 58.03
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPBL, Severe, TICA, n=8717.35 Canadian DollarsStandard Deviation 1661.26
BD-Asthma/RESPIndirect Cost of Asthma by Level of Asthma Severity Per Participant Per 3 Months at BL and 12-month FUPFUP, Severe, TICA, n=7135.16 Canadian DollarsStandard Deviation 285.08
Primary

Indirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)

Participants completed questionnaires within 2 weeks post-recruitment, 4, 8 and 12 months to measure indirect cost of disease, specifically related to productivity. The following questionnaires were used: WPAI helps to determine presenteeism, absenteeism, and total cost calculation (TCC) possible (number of days during the year of study), while VOLP is used to assess the impact of health conditions on lost productivity in monetary units (United states dollars). The following parameters were calculated: Cost of absenteeism due to asthma (CAA), cost of presenteeism due to asthma (CPA), cost of absenteeism due to asthma in whom TCC was possible (CAA TCC), cost of presenteeism due to asthma in whom TCC was possible (CPA TCC), and total indirect cost due to asthma (TICA).

Time frame: BL and at 12-month FUP

Population: Source Population: all par. with asthma diagnosed by respirologist and followed at outpatient asthma clinic of the HSCM and registered in BD-Asthma/RESP. Only par. with available data in each category (represented by n=X in the category title) were analyzed. One third of par. selected were retired. Only 59 were active workers (52 at BL; 40 at FUP).

ArmMeasureGroupValue (MEAN)Dispersion
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)FUP,CPA TCC,n=3717.1 US DollarsStandard Deviation 37.2
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL, CAA, n=52253.3 US DollarsStandard Deviation 847.5
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)FUP, CAA, n=4070.4 US DollarsStandard Deviation 157.6
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL,CPA,n=5016.9 US DollarsStandard Deviation 78.8
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)FUP,CPA, n=3917.1 US DollarsStandard Deviation 37.2
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL,CAA TCC, n=46183.3 US DollarsStandard Deviation 648.2
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)FUP,CAA TCC,n=3776.10 US DollarsStandard Deviation 162.64
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL,CPA TCC, n=4618.4 US DollarsStandard Deviation 82
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)BL,TICA,n=46201.7 US DollarsStandard Deviation 723.7
BD-Asthma/RESPIndirect Cost of Asthma Per Participant Per 3 Months at Baseline (BL) and 12-month Follow-up (FUP)FUP, TICA, n=3793.2 US DollarsStandard Deviation 182.3
Secondary

Work Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points

WPAI is a self-administered instrument to determine the degree to which asthma affected work productivity while at work and affected activities outside of work in the last 7 days and yields 4 types of scores: Absenteeism (work time missed/missed due to other reasons); Presenteeism (actual time worked); Work Productivity Loss (affected productivity while working); and Activity Impairment (affected regular activities). The following parameters were presented: Hours (Hrs) missed due to asthma (HMA), Hrs missed due to other reasons (HMO), and Hrs actually worked (HAW); all in the last 7 days.

Time frame: At BL, 4-Month, 8-Month and 12-Month FUP

Population: Source Population. Only par. with available data in each category (represented by n=X in the category title) were analyzed. Among the 101 par., 35 (35%) were retired and 59 (58%) were working. Only par. working were who completed the WPAI questionnaire were included in the analysis (56 at BL; 49 at 4 months; 37 at 8 months; 44 at FUP).

ArmMeasureGroupValue (MEAN)Dispersion
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time PointsBL, HMO, last 7 days, n=563.3 HoursStandard Deviation 9
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time PointsBL, HMA, last 7 days, n=560.4 HoursStandard Deviation 2.8
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points4-Month FUP, HMA, last 7 days, n=492.4 HoursStandard Deviation 9
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points8-Month FUP, HMA, last 7 days, n=370.9 HoursStandard Deviation 5.3
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points12-Month FUP, HMA, last 7 days, n=440.0 HoursStandard Deviation 0.3
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points4-Month FUP, HMO, last 7 days, n=494.2 HoursStandard Deviation 9.1
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points8-Month FUP, HMO, last 7 days, n=376.1 HoursStandard Deviation 12.8
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points12-Month FUP, HMO, last 7 days, n=444.4 HoursStandard Deviation 10.5
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time PointsBL, HAW, last 7 days, n=5632.9 HoursStandard Deviation 13.4
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points4-Month FUP, HAW, last 7 days, n=4927.6 HoursStandard Deviation 15.8
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points8-Month FUP, HAW, last 7 days, n=3728.1 HoursStandard Deviation 16
BD-Asthma/RESPWork Productivity Loss as Assessed in Hours Using Work Productivity and Activity Impairment (WPAI) During the Specified Time Points12-Month FUP, HAW, last 7 days, n=4433.0 HoursStandard Deviation 16.6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026